OXNARD, Calif., March 27, 2017 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces it will be exhibiting at the 8th Global Drug Delivery & Formulation (DDF) Summit in Berlin, Germany March 27-29, 2017.
“The DDF Summit is among the most prestigious international conferences related to drug formulation and development,” said Rob Davidson, CEO of CURE Pharmaceutical. “We are anxious to share expertise among this elite group of investigators and manufacturers and look forward to potential future developments emanating from this conference.”
About CURE Pharmaceutical
Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility. CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules. The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index. CURE Pharmaceutical is traded under the symbol CURR. For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
About The 8th Global Drug Development & Formulation Summit
The growth of biopharma and patient compliance issues have encouraged us to adopt a drug delivery mindset from discovery right through to production. The host of resulting challenges is being tackled by some of the greatest minds in pharma, academia and technology. Every year we see innovation and breakthroughs at every level of drug development. The DDF Summit brings these inspirational stories to you. Through exclusive case studies, brand new results and in depth analysis you’ll be at the very forefront of modern pharmaceutical development.
The summit features 3 dedicated streams and 60 speakers across 3 days. You’ll find new technologies, concepts and contacts to help you in areas such as:
- Oral delivery of biologics – bioavailability, modeling and innovative drug delivery systems
- Injectability of highly concentrated protein formulations
- Understanding and control of amorphous solid dispersions
- Nanoparticles – preparation, progress and future potential
- Challenges of pediatric drug delivery
- Microneedles and the latest transdermal delivery systems
Complementing the technical streamed sessions, you’ll also have keynotes from industry giants on the bigger picture of where the industry is going. As well as academic and regulatory gurus guiding you through current approval process mine fields. It’s this combination of industry and academic minds with common interests and goals that provide such a richly stimulating and exciting environment.
Forward-looking statements
This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 [email protected]


DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
European Car Sales Surge in March as EV and Hybrid Demand Accelerates
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 



